tetano
Editor, Senior Moderator
Eur J Clin Invest
. 2020 Aug 9;e13378.
doi: 10.1111/eci.13378. Online ahead of print.
Features of severe COVID-19: A systematic review and meta-analysis
Francesco Del Sole[SUP] 1 [/SUP], Alessio Farcomeni[SUP] 2 [/SUP], Lorenzo Loffredo[SUP] 1 [/SUP], Roberto Carnevale[SUP] 3 4 [/SUP], Danilo Menichelli[SUP] 1 [/SUP], Tommasa Vicario[SUP] 5 6 [/SUP], Pasquale Pignatelli[SUP] 1 4 [/SUP], Daniele Pastori[SUP] 1 [/SUP]
Affiliations
Abstract
Background: To systematically review clinical and biochemical characteristics associated with the severity of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19).
Materials and methods: Systematic review of observational studies from PubMed, ISI Web of Science, SCOPUS and Cochrane databases including people affected by COVID-19 and reporting data according to the severity of the disease. Data were combined with odds ratio (OR) and metanalysed. Severe COVID-19 was defined by acute respiratory distress syndrome, intensive care unit admission and death.
Results: We included 12 studies with 2794 patients, of whom 596 (21.33%) had severe disease. A slightly higher age was found in severe vs non-severe disease. We found that prevalent cerebrovascular disease (odds ratio [OR] 3.66, 95% confidence interval [CI] 1.73-7.72), chronic obstructive pulmonary disease (OR: 2.39, 95% CI 1.10-5.19), prevalent cardiovascular disease (OR: 2.84, 95% CI 1.59-5.10), diabetes (OR: 2.78, 95% CI 2.09-3.72), hypertension (OR: 2.24, 95% CI 1.63-3.08), smoking (OR: 1.54, 95% CI 1.07-2.22) and male sex (OR: 1.22, 95% CI 1.01-1.49) were associated with severe disease. Furthermore, increased procalcitonin (OR: 8.21, 95% CI 4.48-15.07), increased D-Dimer (OR: 5.67, 95% CI 1.45-22.16) and thrombocytopenia (OR: 3.61, 95% CI 2.62-4.97) predicted severe infection.
Conclusion: Characteristics associated with the severity of SARS-CoV-2 infection may allow an early identification and management of patients with poor outcomes.
Keywords: SARS-CoV-2; d-dimer; infection; procalcitonin; severity; sex; thrombocytopenia.
. 2020 Aug 9;e13378.
doi: 10.1111/eci.13378. Online ahead of print.
Features of severe COVID-19: A systematic review and meta-analysis
Francesco Del Sole[SUP] 1 [/SUP], Alessio Farcomeni[SUP] 2 [/SUP], Lorenzo Loffredo[SUP] 1 [/SUP], Roberto Carnevale[SUP] 3 4 [/SUP], Danilo Menichelli[SUP] 1 [/SUP], Tommasa Vicario[SUP] 5 6 [/SUP], Pasquale Pignatelli[SUP] 1 4 [/SUP], Daniele Pastori[SUP] 1 [/SUP]
Affiliations
- PMID: 32860457
- DOI: 10.1111/eci.13378
Abstract
Background: To systematically review clinical and biochemical characteristics associated with the severity of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19).
Materials and methods: Systematic review of observational studies from PubMed, ISI Web of Science, SCOPUS and Cochrane databases including people affected by COVID-19 and reporting data according to the severity of the disease. Data were combined with odds ratio (OR) and metanalysed. Severe COVID-19 was defined by acute respiratory distress syndrome, intensive care unit admission and death.
Results: We included 12 studies with 2794 patients, of whom 596 (21.33%) had severe disease. A slightly higher age was found in severe vs non-severe disease. We found that prevalent cerebrovascular disease (odds ratio [OR] 3.66, 95% confidence interval [CI] 1.73-7.72), chronic obstructive pulmonary disease (OR: 2.39, 95% CI 1.10-5.19), prevalent cardiovascular disease (OR: 2.84, 95% CI 1.59-5.10), diabetes (OR: 2.78, 95% CI 2.09-3.72), hypertension (OR: 2.24, 95% CI 1.63-3.08), smoking (OR: 1.54, 95% CI 1.07-2.22) and male sex (OR: 1.22, 95% CI 1.01-1.49) were associated with severe disease. Furthermore, increased procalcitonin (OR: 8.21, 95% CI 4.48-15.07), increased D-Dimer (OR: 5.67, 95% CI 1.45-22.16) and thrombocytopenia (OR: 3.61, 95% CI 2.62-4.97) predicted severe infection.
Conclusion: Characteristics associated with the severity of SARS-CoV-2 infection may allow an early identification and management of patients with poor outcomes.
Keywords: SARS-CoV-2; d-dimer; infection; procalcitonin; severity; sex; thrombocytopenia.